Description
The method employs sandwich ELISA technique. Human SARS-CoV-2 S protein RBD is pre-coated onto microwells. Human ACE2 and Inhibitor in the Samples compete and Inhibitor Control are pipetted into microwells. The Inhibitor in the Samples and Control will inhibit the ACE2 from binding to the SARS-CoV-2 s protein RBD to form a complex. After incubation the wells are washed and HRP-conjugated Detection antibody is pipetted and incubated to form a complex. After washing microwells in order to remove any non-specific binding, the substrate solution (TMB) is added to microwells and color develops in inverse proportional to the amount of Inhibitor in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm